SEMA3A and osteoporosis: Our study demonstrates for the first time that the Sema3A-NRP1-β-catenin signalling axis plays a regulatory role in the development of disuse osteoporosis, through which naringin could be a promising therapeutic agent in the clinical prevention of disuse osteoporosis.